# A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)

> **NCT00524537** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 5025 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00524537
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 5025 (ACTUAL)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00524537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00524537, "A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT00524537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*